Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression

被引:33
作者
Budhram-Mahadeo, Vishwanie S. [1 ]
Bowen, Samantha [1 ]
Lee, Sonia [1 ]
Perez-Sanchez, Christina [1 ]
Ensor, Elizabeth [1 ]
Morris, Peter J. [1 ]
Latchman, David S. [1 ]
机构
[1] UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England
基金
英国医学研究理事会;
关键词
FAMILY TRANSCRIPTION FACTOR; NEURONAL PROCESS OUTGROWTH; DOMAIN FACTOR BRN-3B; GENE-EXPRESSION; IN-VITRO; DIFFERENTIAL REGULATION; SENSORY NEURONS; CANCER; ACTIVATION; DEATH;
D O I
10.1093/nar/gkl878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Brn-3a and Brn-3b transcription factor have opposite and antagonistic effects in neuroblastoma cells since Brn-3a is associated with differentiation whilst Brn-3b enhances proliferation in these cells. In this study, we demonstrate that like Brn-3a, Brn-3b physically interacts with p53. However, whereas Brn-3a repressed p53 mediated Bax expression but cooperated with p53 to increase p21(cip1/waf1), this study demonstrated that co-expression of Brn-3b with p53 increases trans-activation of Bax promoter but not p21(cip1/waf1). Consequently co-expression of Brn-3b with p53 resulted in enhanced apoptosis, which is in contrast to the increased survival and differentiation, when Brn-3a is co-expressed with p53. For Brn-3b to cooperate with p53 on the Bax promoter, it requires binding sites that flank p53 sites on this promoter. Furthermore, neurons from Brn-3b knock-out (KO) mice were resistant to apoptosis and this correlated with reduced Bax expression upon induction of p53 in neurons lacking Brn-3b compared with controls. Thus, the ability of Brn-3b to interact with p53 and modulate Bax expression may demonstrate an important mechanism that helps to determine the fate of cells when p53 is induced.
引用
收藏
页码:6640 / 6652
页数:13
相关论文
共 65 条
[1]   p53-dependent pathways of apoptosis [J].
Benchimol, S .
CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1049-1051
[2]   ASPP1 and ASPP2: Common activators of p53 family members [J].
Bergamaschi, D ;
Samuels, Y ;
Jin, BQ ;
Duraisingham, S ;
Crook, T ;
Lu, X .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (03) :1341-1350
[3]   Functions of the BRGA1 and BRCA2 genes [J].
Bertwistle, D ;
Ashworth, A .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) :14-20
[4]   The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells [J].
Budhram-Mahadeo, V ;
Ndisang, D ;
Ward, T ;
Weber, BL ;
Latchman, DS .
ONCOGENE, 1999, 18 (48) :6684-6691
[5]   p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor [J].
Budhram-Mahadeo, V ;
Morris, PJ ;
Smith, MD ;
Midgley, CA ;
Boxer, LM ;
Latchman, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (21) :15237-15244
[6]   The Brn-3a POU family transcription factor stimulates p53 gene expression in human and mouse tumour cells [J].
Budhram-Mahadeo, V ;
Morris, P ;
Ndisang, D ;
Irshad, S ;
Lozano, G ;
Pedley, B ;
Latchman, DS .
NEUROSCIENCE LETTERS, 2002, 334 (01) :1-4
[7]   POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element [J].
Budhram-Mahadeo, V ;
Parker, M ;
Latchman, DS .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :1029-1041
[8]   Targeting Brn-3b in breast cancer therapy [J].
Budhram-Mahadeo, VS ;
Latchman, DS .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (01) :15-25
[9]   CELL-CYCLE ARREST AND MORPHOLOGICAL-DIFFERENTIATION CAN OCCUR IN THE ABSENCE OF APOPTOSIS IN A NEURONAL CELL-LINE [J].
BUDHRAMMAHADEO, V ;
LILLYCROP, KA ;
LATCHMAN, DS .
NEUROSCIENCE LETTERS, 1994, 165 (1-2) :18-22
[10]   ACTIVATION OF THE ALPHA-INTERNEXIN PROMOTER BY THE BRN-3A TRANSCRIPTION FACTOR IS DEPENDENT ON THE N-TERMINAL REGION OF THE PROTEIN [J].
BUDHRAMMAHADEO, V ;
MORRIS, PJ ;
LAKIN, ND ;
THEIL, T ;
CHING, GY ;
LILLYCROP, KA ;
MOROY, T ;
LIEM, RKH ;
LATCHMAN, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (06) :2853-2858